| Symbol | HUMA |
|---|---|
| Name | HUMACYTE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, North Carolina, 27713, United States |
| Telephone | +1 919 313-9633 |
| Fax | — |
| — | |
| Website | https://www.humacyte.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001818382 |
| Description | Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Additional info from NASDAQ: |
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Read moreJones Keith Anthony 🟢 acquired 10.0K shares of Humacyte, Inc. (HUMA) at $0.69 Transaction Date: Aug 20, 2026 | Filing ID: 361081
Read moreJones Keith Anthony 🟢 acquired 30.0K shares of Humacyte, Inc. (HUMA) at $0.59 Transaction Date: Aug 17, 2026 | Filing ID: 356847
Read moreHumacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
Read moreBoard-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
Read moreHumacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Read moreHumacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07141641 | Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV… | — | Vascular Diseases | Temporarily_Not_Available | — | — | ClinicalTrials.gov |
| NCT03631056 | Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV… | — | Vascular System Injuries | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07762794 | Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real Wor… | Phase4 | Vascular Injury | Not_Yet_Recruiting | 2026-09-01 | 2030-09-01 | ClinicalTrials.gov |
| NCT07762313 | An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular… | Phase3 | Vascular Trauma | Not_Yet_Recruiting | 2026-09-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07730528 | Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Enginee… | Phase2 | Coronary Artery Disease | Not_Yet_Recruiting | 2026-09-01 | 2030-09-01 | ClinicalTrials.gov |
| NCT05908084 | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With… | Phase3 | End Stage Renal Disease (ESRD) | Active_Not_Recruiting | 2023-09-07 | 2028-06-01 | ClinicalTrials.gov |
| NCT05873959 | An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV fo… | — | Trauma | Completed | 2023-05-01 | 2024-01-15 | ClinicalTrials.gov |
| NCT04135417 | Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for D… | Phase2 | Renal Failure | Completed | 2019-11-12 | 2022-03-02 | ClinicalTrials.gov |
| NCT03005418 | Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Tr… | Phase2 | Trauma | Completed | 2018-09-01 | 2026-05-15 | ClinicalTrials.gov |
| NCT03183245 | Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for He… | Phase3 | Renal Failure | Completed | 2017-09-29 | 2025-06-19 | ClinicalTrials.gov |
| NCT02887859 | Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD | Phase2 | Peripheral Artery Disease | Completed | 2016-12-20 | 2023-12-01 | ClinicalTrials.gov |
| NCT02644941 | Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits fo… | Phase3 | Renal Failure | Completed | 2016-05-24 | 2023-09-01 | ClinicalTrials.gov |
| NCT01872208 | Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee… | Na | Peripheral Arterial Disease | Completed | 2013-10-10 | 2024-07-18 | ClinicalTrials.gov |
| NCT01840956 | Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patient… | Phase1 | End-stage Renal Disease | Completed | 2013-05-23 | 2016-04-28 | ClinicalTrials.gov |
| NCT01744418 | Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis… | Na | End-stage Renal Disease | Completed | 2012-11-22 | 2024-03-26 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ePTFE graft | Other | Phase PHASE3 | Renal Failure | COMPLETED | NCT02644941 |
| Human Acellular Vessel (HAV) | Other | Phase PHASE3 | Renal Failure | COMPLETED | NCT02644941 |
| Acellular Tissue Engineered Vessel (Symvess) | Other | Phase PHASE3 | Vascular Trauma | NOT_YET_RECRUITING | NCT07762313 |
| Acellular Tissue Engineered Vessel | Other | Phase PHASE4 | Vascular Injury | NOT_YET_RECRUITING | NCT07762794 |
| Acellular Tissue Engineered Vessel (ATEV) | Other | Phase PHASE2 | Trauma | COMPLETED | NCT03005418 |
| Humacyte Coronary Tissue Engineered Vessel (CTEV) | Other | Phase PHASE2 | Coronary Artery Disease | NOT_YET_RECRUITING | NCT07730528 |
| AVF | Other | Phase PHASE3 | End Stage Renal Disease (ESRD) | ACTIVE_NOT_RECRUITING | NCT05908084 |
| Acellular Tissue Engineered Vessel (ATEV) | Other | Phase PHASE3 | End Stage Renal Disease (ESRD) | ACTIVE_NOT_RECRUITING | NCT05908084 |
| Human Acellular Vessel (HAV) | Other | Phase PHASE2 | Trauma | ACTIVE_NOT_RECRUITING | NCT03005418 |
| HAVG | Other | Phase PHASE1 | End-stage Renal Disease | COMPLETED | NCT01840956 |
| HAV | Other | Phase PHASE2 | Renal Failure | COMPLETED | NCT04135417 |
| HAV implantation | Other | Approved | Peripheral Arterial Disease | COMPLETED | NCT01872208 |
| HAVG graft implantation | Other | Approved | End-stage Renal Disease | COMPLETED | NCT01744418 |
| HAV implantation | Other | Preclinical | Trauma | COMPLETED | NCT05873959 |
| AVF | Other | Phase PHASE3 | End Stage Renal Disease (ESRD) | RECRUITING | NCT05908084 |
| Acellular Tissue Engineered Vessel (ATEV) | Other | Phase PHASE3 | End Stage Renal Disease (ESRD) | RECRUITING | NCT05908084 |
| ePTFE graft | Other | Phase PHASE3 | Renal Failure | COMPLETED | NCT02644941 |
| Human Acellular Vessel (HAV) | Other | Phase PHASE3 | Renal Failure | COMPLETED | NCT02644941 |
| Human Acellular Vessel (HAV) | Other | Phase PHASE2 | Peripheral Artery Disease | COMPLETED | NCT02887859 |
| Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV) | Other | Preclinical | Vascular System Injuries | APPROVED_FOR_MARKETING | NCT03631056 |
| Acellular Tissue Engineered Vessel (ATEV) | Other | Preclinical | Vascular Diseases | TEMPORARILY_NOT_AVAILABLE | NCT07141641 |
| Hemodialysis | Other | Phase PHASE3 | Renal Failure | COMPLETED | NCT03183245 |
| Arteriovenous fistula (AVF) | Other | Phase PHASE3 | Renal Failure | COMPLETED | NCT03183245 |
| Human Acellular Vessel (HAV) | Other | Phase PHASE3 | Renal Failure | COMPLETED | NCT03183245 |
| AVF | OTHER | Phase PHASE3 | End Stage Renal Disease (ESRD) | RECRUITING | NCT05908084 |
| Acellular Tissue Engineered Vessel (ATEV) | BIOLOGICAL | Preclinical | Vascular Diseases | TEMPORARILY_NOT_AVAILABLE | NCT07141641 |
| HAV | BIOLOGICAL | Phase PHASE2 | Renal Failure | COMPLETED | NCT04135417 |
| Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV) | BIOLOGICAL | Preclinical | Vascular System Injuries | APPROVED_FOR_MARKETING | NCT03631056 |
| Hemodialysis | OTHER | Phase PHASE3 | Renal Failure | COMPLETED | NCT03183245 |
| Arteriovenous fistula (AVF) | PROCEDURE | Phase PHASE3 | Renal Failure | COMPLETED | NCT03183245 |
| ePTFE graft | DEVICE | Phase PHASE3 | Renal Failure | COMPLETED | NCT02644941 |
| Human Acellular Vessel (HAV) | BIOLOGICAL | Phase PHASE3 | Renal Failure | COMPLETED | NCT03183245 |
| HAV implantation | BIOLOGICAL | Preclinical | Trauma | COMPLETED | NCT05873959 |
| HAVG | BIOLOGICAL | Phase PHASE1 | End-stage Renal Disease | COMPLETED | NCT01840956 |
| HAVG graft implantation | DEVICE | Approved | End-stage Renal Disease | COMPLETED | NCT01744418 |